Novilla Pharmaceuticals

Executive Summary

Novilla Pharmaceuticals is a privately-held drug delivery company based in Princeton, NJ, leveraging a proprietary AI algorithm to design novel therapeutics. Its lead candidate, NOV-1776, recently completed human clinical trials demonstrating a 212% improvement in efficacy versus the standard of care, with minimal systemic exposure (<1%) and no gastrointestinal adverse events. This profile suggests a potential best-in-class treatment for gastrointestinal or topical indications, possibly addressing a high unmet need. The AI-driven platform enables rapid optimization of drug candidates, positioning Novilla to develop a pipeline of targeted therapies with enhanced safety and efficacy. While the company is still in early stages, the compelling clinical data for NOV-1776 and the scalability of its AI platform present attractive opportunities for partnership or further development.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 2/3 Trial for NOV-177670% success
• Q4 2026Strategic Partnership or Licensing Deal60% success
• Q3 2026Regulatory Meeting (e.g., Pre-Phase 3/NDA) with FDA75% success